It is worth investigating strictinin as a ROR1 inhibitor in other cancers that display elevated levels of ROR1 expression to further expand on the findings in this study that identify the anti-cancerous effects of strictinin in ARneg-AI prostate cancer. Here, ROR1 is linked to prostate carcinoma.